Highlighting the Phase 1 Pharmacokinetics & Safety Study of TRPH-222 in Patients with Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma

Time: 12:00 pm
day: Track C - Day 2


  • Summarise the SMARTag technology and Phase 1 study design
  • Review of the safety and efficacy of TRPH-222 in R/R NHL
  • Presenting our thoughts on future directions for ADCs using novel payload linkers and moving beyond cytotoxic payloads